Measurement of S100B protein: evaluation of a new prototype on a bioMérieux Vidas® 3 analyzer

Charlotte Oris; Russel Chabanne; Julie Durif; Samy Kahouadji; Marina Brailova; Vincent Sapin; Damien Bouvier

doi:10.1515/cclm-2018-1217

Article

Measurement of S100B protein: evaluation of a new prototype on a bioMérieux Vidas^® 3 analyzer

Charlotte Oris , Russel Chabanne , Julie Durif , Samy Kahouadji , Marina Brailova , Vincent Sapin and Damien Bouvier

Published/Copyright: February 14, 2019

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 57 Issue 8

Abstract

Background

The addition of S100B protein to guidelines for the management of mild traumatic brain injury (mTBI) decreases the amount of unnecessary computed tomography (CT) scans with a significant decrease in radiation exposure and an increase in cost savings. Both DiaSorin and Roche Diagnostics have developed automated assays for S100B determination. Recently, bioMérieux developed a prototype immunoassay for serum S100B determination. For the first time, we present the evaluation of the S100B measurement using a bioMérieux Vidas^® 3 analyzer.

Methods

We evaluated the matrix effects of serum and plasma, and their stability after storage at 2–8 °C, −20 °C and −80 °C. The new measurement prototype (bioMérieux) was compared with an established one (Roche Diagnostics), and a precision study was also conducted. Lastly, clinical diagnostics performance of the bioMérieux and Roche Diagnostics methods were compared for 80 patients referred to the Emergency Department for mTBI.

Results

Stability after storage at 2–8 °C, −20 °C, and −80 °C and validation of the serum matrix were demonstrated. The bioMérieux analyzer was compared to the Roche Diagnostics system, and the analytical precision was found to be efficient. Clinical diagnosis performance evaluation confirmed the predictive negative value of S100B in the management of mTBI.

Conclusions

The study’s data are useful for interpreting serum S100B results on a bioMérieux Vidas^® 3 analyzer.

Keywords: assay comparison; Cobas; sample stability; S100B; Vidas

Corresponding author: Damien, MD-PhD, Biochemistry and Molecular Biology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France

Acknowledgments

We thank the Emergency Department and the Neurological Intensive Care Unit at Clermont-Ferrand Hospital for their help in specimen collection. We wish to acknowledge the excellent technical assistance of Laure Allard, Frédérique Raymond and Corinne Perret.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This work was supported by the bioMérieux company.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Brenner DJ. Computed tomography an increasing source of radiation exposure. N Engl J Med 2007;357:2277–84.10.1056/NEJMra072149Search in Google Scholar

2. Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, et al. Cancer risk in 680 000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. Br Med J 2013;346:f2360.10.1136/bmj.f2360Search in Google Scholar

3. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012;380:499–505.10.1016/S0140-6736(12)60815-0Search in Google Scholar

4. Calcagnile O, Anell A, Undén J. The addition of S100B to guidelines for management of mild head injury is potentially cost saving. BMC Neurol 2016;16:200.10.1186/s12883-016-0723-zSearch in Google Scholar

5. Stiell IG, Wells GA, Vandemheen K, Clement C, Lesiuk H, Laupacis A, et al. The Canadian CT Head Rule for patients with minor head injury. Lancet 2001;357:1391–6.10.1016/S0140-6736(00)04561-XSearch in Google Scholar

6. Undén J, Romner B. Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: an evidence-based review and meta-analysis. J Head Trauma Rehabil 2010;25:228–40.10.1097/HTR.0b013e3181e57e22Search in Google Scholar

7. Oris C, Pereira B, Durif J, Simon-Pimmel J, Castellani C, Manzano S, et al. The Biomarker S100B and mild traumatic brain injury: a meta-analysis. Pediatrics 2018;141:e20180037.10.1542/peds.2018-0037Search in Google Scholar

8. Undén L, Calcagnile O, Undén J, Reinstrup P, Bazarian J. Validation of the Scandinavian guidelines for initial management of minimal, mild and moderate traumatic brain injury in adults. BMC Med 2015;13:292.10.1186/s12916-015-0533-ySearch in Google Scholar

9. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995;37:417–29.10.1016/0361-9230(95)00040-2Search in Google Scholar

10. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637–68.10.1016/S1357-2725(01)00046-2Search in Google Scholar

11. Laribi S, Kansao J, Borderie D, Collet C, Deschamps P, Ababsa R, et al. S100B blood level measurement to exclude cerebrallesions after minor head injury: the multicenter STIC-S100 French study. Clin Chem Lab Med 2014;52:527–36.10.1515/cclm-2013-0621Search in Google Scholar

12. Smit LH, Korse CM, Bonfrer JM. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 2005;20:34–42.10.1177/172460080502000106Search in Google Scholar

13. Bouvier D, Duret T, Rouzaire P, Jabaudon M, Rouzaire M, Nourrisson C, et al. Preanalytical, analytical, gestational and pediatric aspects of the S100B immuno-assays. Clin Chem Lab Med 2016;54:833–42.10.1515/cclm-2015-0771Search in Google Scholar

14. Tort AB, Dietrich MO, Gonçalves CA, Souza DO, Portela LV. Influence of anticoagulants on the measurement of S100B protein in blood. Clin Biochem 2003;36:629–32.10.1016/S0009-9120(03)00107-3Search in Google Scholar

15. Raabe A, Kopetsch O, Groß U, Zimmermann M, Gebhart P. Measurements of serum S-100B protein: effects of storage time and temperature on pre-analytical stability. Clin Chem Lab Med 2003;41:700–3.10.1515/CCLM.2003.106Search in Google Scholar PubMed

16. Djukanovic D, Hofmann U, Sucker A, Schadendorf D. Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing. Br J Dermatol 2001;145:1030–1.10.1046/j.1365-2133.2001.04545.xSearch in Google Scholar PubMed

17. Feriel J, Adamo F, Monneret D, Trehel-Tursis V, Favard S, Tsé C, et al. S100B protein concentration measurement according to two different immunoassays. Clin Chem Lab Med 2015;53: e169–71.10.1515/cclm-2014-1090Search in Google Scholar PubMed

18. Delefortrie Q, Lejeune F, Kerzmann B, Levy R, Adam J-F, Sottiaux T, et al. Evaluation of the Roche® Elecsys and the Diasorin® Liaison S100 kits in the management of mild head injury in the emergency room. Clin Biochem 2018;52:123–30.10.1016/j.clinbiochem.2017.11.004Search in Google Scholar PubMed

19. Biberthaler P, Linsenmeier U, Pfeifer K-J, Kroetz M, Mussack T, Kanz K-G, et al. Serum S-100B concentration provides additional information for the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock Augusta 2006;25:446–53.10.1097/01.shk.0000209534.61058.35Search in Google Scholar PubMed

20. Mercier E, Boutin A, Lauzier F, Fergusson DA, Simard J-F, Zarychanski R, et al. Predictive value of S-100β protein for prognosis in patients with moderate and severe traumatic brain injury: systematic review and meta-analysis. Br Med J 2013;346:f1757.10.1136/bmj.f1757Search in Google Scholar PubMed

21. Allouchery G, Moustafa F, Roubin J, Pereira B, Schmidt J, Raconnat J, et al. Clinical validation of S100B in the management of a mild traumatic brain injury: issues from an interventional cohort of 1449 adult patients. Clin Chem Lab Med 2018;56:1897–904.10.1515/cclm-2018-0471Search in Google Scholar PubMed

22. Mazer CD, Novoshinov S, Tsoporis J, Izhar S, Tousignant C, Latter D, et al. Heparin influences s100b protein levels in blood during cardiac surgery. Can J Anesth 2007;54:44607.10.1007/BF03020019Search in Google Scholar

23. Wang S, Wang L, Zhang X, Wang C, Zheng G, Wu W, et al. Effects of subcutaneous low molecular weight heparin and intravenous unfractionated heparin on serum S100 concentrations in patients with cerebrovascular diseases. Clin Chem Lab Med 2012;50:525–8.10.1515/cclm.2011.794Search in Google Scholar PubMed

24. Steiner J, Marquardt N, Pauls I, Schiltz K, Rahmoune H, Bahn S, et al. Human CD8(+) T cells and NK cells express and secrete S100B upon stimulation. Brain Behav Immun 2011;25:1233–41.10.1016/j.bbi.2011.03.015Search in Google Scholar PubMed

25. Padoan A, Zaninotto M, Piva E, Sciacovelli L, Aita A, Tasinato A, et al. Quality of plasma samples and BD Vacutainer Barricor tubes: Effects of centrifugation. Clin Chim Acta 2018;483:271–4.10.1016/j.cca.2018.05.018Search in Google Scholar PubMed

26. Bouvier D, Castellani C, Fournier M, Dauphin J-B, Ughetto S, Breton M, et al. Reference ranges for serum S100B protein during the first three years of life. Clin Biochem 2011;44:927–9.10.1016/j.clinbiochem.2011.05.004Search in Google Scholar PubMed

Received: 2018-11-13

Accepted: 2019-01-18

Published Online: 2019-02-14

Published in Print: 2019-07-26

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/cclm-2018-1217

Keywords for this article

assay comparison; Cobas; sample stability; S100B; Vidas